Your browser is not supported for the Live Clock Timer, please visit the Support Center for support.

Coronavirus:antiviral drug developed,claims Glenmark Pharmaceuticals

In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a
research-led, integrated global pharmaceutical company, today announced the launch of antiviral drug
Favipiravir (brand name FabiFlu®) for the treatment of mild to moderate COVID-19 patients. Glenmark
has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu® the
first oral Favipiravir-approved medication in India for the treatment of COVID-19.

Favipiravir is backed by strong clinical evidence showing encouraging results in patients with mild to
moderate COVID-19.

The antiviral offers broad spectrum RNA virus coverage 2 with clinical improvement
noted across age groups 20 to >90 years. 3 Favipiravir can be used in COVID-19 patients with co-morbid
conditions such as diabetes and heart disease with mild to moderate COVID 19 symptoms. 3 It offers
rapid reduction in viral load within 4 days 1,4 and provides faster symptomatic and radiological
improvement. 1,4,5 Of most importance, Favipiravir has shown clinical improvement of up to 88% in
COVID-19 mild to moderate COVID 19 cases. 3
Glenmark successfully developed the active pharmaceutical ingredient (API) and the formulation for
FabiFlu® through its own in-house R&D team. Glenmark filed the product for clinical trial with India’s
drug regulator DCGI and became the first pharmaceutical company in India to receive approval for
conducting phase 3 clinical trial on mild to moderate COVID-19 patients.

Commenting on the significance of this development, Mr. Glenn Saldanha, Chairman and Managing
Director of Glenmark Pharmaceuticals Ltd., said, “This approval comes at a time when cases in India
are spiralling like never before, putting a tremendous pressure on our healthcare system. We hope the
availability of an effective treatment such as FabiFlu® will considerably help assuage this pressure,
and offer patients in India a much needed and timely therapy option.”

He added, “FabiFlu® has demonstrated an encouraging response in mild to moderate COVID-19
patients during clinical trials. Moreover, it is orally administered, and so it serves as a more convenient
treatment option over other intravenously administered medications. Glenmark will work closely with
the government and medical community to make FabiFlu® quickly accessible to patients across the
Favipiravir is approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus
infections. It has a unique mechanism of action: it is converted into an active phosphoribosylated form
(favipiravir-RTP) in cells and recognized as a substrate by viral RNA polymerase, thereby inhibiting RNA
polymerase activity.
Most patients exhibiting mild to moderate symptoms can benefit from FabiFlu® use. The drug will be
available as a prescription-based medication for INR 103/tablet, with recommended dose being 1800 mg
twice daily on day 1, followed by 800 mg twice daily up to day 14.
Earlier last month, Glenmark also announced that it is conducting another clinical trial to evaluate the
efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalized
adult COVID-19 patients in India.

More News from City Talk